Human parvovirus B19 as a causative agent for rheumatoid arthritis.

Human parvovirus B19 (B19) DNA was detected in the synovial tissues in 30 of 39 patients with rheumatoid arthritis (RA), and infrequently in those with osteoarthritis and traumatic joints. On the other hand, the expression of the B19 antigen VP-1 was specific (27/27) in RA synovium with active synovial lesions, but not in osteoarthritis and controls. The target cells of B19 were macrophages, follicular dendritic cells, T cells, and B cells, but not synovial lining cells in the synovium. B19-negative bone marrow cells, tonsil cells, and macrophage cell line U-937 cells became positive for the expression of VP-1, and more productive for interleukin 6 and tumor necrosis factor alpha when cocultured with RA synovial cells. The expression of VP-1 and the production of interleukin 6 and tumor necrosis factor alpha was significantly inhibited by the addition of neutralizing antibody for B19, suggesting that B19 detected in RA synovial cells is infective. B19 is involved in the initiation and perpetuation of RA synovitis, leading to joint lesions.

[1]  K. Hedman,et al.  Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy , 1997, The Lancet.

[2]  K. Matsushima,et al.  Expression and regulation of monocyte chemoattractant protein‐1 by human eosinophils , 1997, European journal of immunology.

[3]  F. Breedveld,et al.  Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. , 1997, Arthritis and rheumatism.

[4]  I. McInnes,et al.  Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis , 1997, Nature Medicine.

[5]  T. Hirano,et al.  A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression , 1996, Journal of virology.

[6]  T. Sawai,et al.  Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. , 1995, Annals of the rheumatic diseases.

[7]  T. Koerner,et al.  Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. , 1995, The Journal of infectious diseases.

[8]  K. Ohta,et al.  Chemotactic agonists induce cytokine generation in eosinophils. , 1995, Journal of immunology.

[9]  R. Atkins,et al.  A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  N. Young,et al.  Erythrocyte P antigen: cellular receptor for B19 parvovirus. , 1993, Science.

[11]  S. Naides.  Viral infection including HIV and AIDS. , 1993, Current opinion in rheumatology.

[12]  E. Moxon,et al.  Population-based study of non-typable Haemophilus influenzae invasive disease in children and neonates , 1993, The Lancet.

[13]  K. Saag,et al.  Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. , 1993, The Journal of infectious diseases.

[14]  D. Ferguson,et al.  Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: Evidence of cell death by apoptosis , 1993, The Journal of pathology.

[15]  A. Cope,et al.  Possible induction of systemic lupus erythematosus by human parvovirus. , 1992, Annals of the rheumatic diseases.

[16]  L. Corman,et al.  Polyarteritis nodosa and parvovirus B19 infection , 1992, The Lancet.

[17]  D. W. Jenkins,et al.  Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. , 1989, The New England journal of medicine.

[18]  K. Sugamura,et al.  Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver , 1989, Journal of virology.

[19]  I. Saito,et al.  Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome , 1989, The Journal of experimental medicine.

[20]  A. Woolf,et al.  Clinical manifestations of human parvovirus B19 in adults. , 1989, Archives of internal medicine.

[21]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[22]  A. Woolf,et al.  HUMAN PARVOVIRUS ARTHROPATHY , 1985, The Lancet.

[23]  D. Reid,et al.  HUMAN PARVOVIRUS-ASSOCIATED ARTHRITIS: A CLINICAL AND LABORATORY DESCRIPTION , 1985, The Lancet.

[24]  R. Humphries,et al.  Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. , 1984, The Journal of clinical investigation.

[25]  H. Radzun,et al.  Monoclonal antibody Ki-M4 specifically recognizes human dendritic reticulum cells (follicular dendritic cells) and their possible precursor in blood , 1983 .

[26]  R. Purcell,et al.  A human parvovirus-like virus inhibits haematopoietic colony formation in vitro , 1983, Nature.

[27]  H. J. Goldsmith,et al.  RE-USE OF DISPOSABLE DIALYSERS , 1976, The Lancet.

[28]  D. Porter,et al.  The pathogenesis of Aleutian disease of mink. 3. Immune complex arteritis. , 1973, The American journal of pathology.

[29]  Copland Jg,et al.  SPREAD OF VIRUS HEPATITIS. , 1964 .

[30]  R. Magendie,et al.  History of a Case of Hydrophobia, treated at the Hotel Dieu at Paris, by an injection of water into the veins. , 1823 .